28. September 2020 | 10:15 CET
BioNTech, NEL ASA, Silver Viper: Profit lies in purchasing
As is well known, timing is of paramount importance for the stock market. Investors who look to take a position always look for the best possible entry point. Rarely do even experienced stock market traders succeed in hitting the low point before the price rises. In connection with the current Corona Pandemic and the uncertainties as to how the course of a possible second wave of infection will develop, there have already been considerable price fluctuations and entry opportunities on the stock markets in recent weeks.
time to read: 2 minutes by Mario Hose
Investors enable growth
The Canadian company Silver Viper has seen a significant performance in its share price over the past 12 months. In connection with a financing round from 2019, the company can now hope for a further inflow of up to CAD 2.8 million. The financing included an early conversion right of warrants as soon as the share price trades at an average of at least CAD 0.70 for ten consecutive days. This condition was met on 15 September 2020 and the holders of the warrants now have until 8 October to subscribe for the new shares.
"I am very proud of the progress our team has made over the last year. The financing last September was done at 25 cents and we recently hit an all-time high of 85 cents," stated Steve Cope, CEO of Silver Viper and continued: "The majority of the La Virginia project has never seen any modern exploration and we will continue to not only expand on our discoveries at El Rubi but also continue to test the other drill-ready anomalies that we have identified through our surface mapping and sampling programs. With a number of catalysts expected before the end of the year, we fully expect to continue to add value to the company. I would like to thank all of our shareholders for their continued support."
Hydrogen for the ecosystem
The Norwegian plant manufacturer NEL ASA is now one of the best-known suppliers to the global hydrogen ecosystem. In recent years, investors have enabled the company to grow in several financing rounds. From a penny stock, the value of the share peaked at over EUR 2.15.
Currently, the shares are changing hands at around 1.45 EUR. Despite political support with government funding, there has been profit-taking in recent weeks. The fear of further restrictions in the fight against the Corona Pandemic is causing general concern. The decline in the share price may offer an entry opportunity.
Development in full swing
The BioNTech share offers investors the opportunity to participate in a vaccine producer. The German company receives government funding and is considered one of the world's leading pharmaceutical teams in the fight against Covid-19. BioNTech recently acquired production facilities with 300 employees from Novartis.
All areas of the company are geared towards success. It seems that it will not be long before approval is granted. BioNTech is already valued at over USD 15 billion, but as infection rates rise, the need for vaccination will continue to increase. For politicians and industry, the provision of a vaccine will be the end of the restrictions.